Viking Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Viking Therapeutics (VKTX) Briefly Falls to Low
November 8, 2018 10:41 AM ESTViking Therapeutics (NASDAQ: VKTX) Briefly Falls to Low
... MoreViking Therapeutics (VKTX) Tops Q3 EPS by 1c
November 7, 2018 4:53 PM ESTViking Therapeutics (NASDAQ: VKTX) reported Q3 EPS of ($0.11), $0.01 better than the analyst estimate of ($0.12).
"The third quarter was an exciting period for Viking as we made several important announcements regarding our pipeline programs," stated Brian Lian, Ph.D., chief executive officer of Viking Therapeutics. "With our VK2809 program for NASH, we announced topline data from a Phase 2 trial in patients with NAFLD and... More
